@article{dd44e8cf36af400289e01bc6380eba9f,
title = "No evidence for a role of the peroxisome proliferator-activated receptor gamma (PPARG) and adiponectin (ADIPOQ) genes in antipsychotic-induced weight gain",
abstract = "Antipsychotics frequently cause changes in glucose metabolism followed by development of weight gain and/or diabetes. Recent findings from our group indicated an influence of glucose-related genes on this serious side effect. With this study, we aimed to extend previous research and performed a comprehensive study on the peroxisome proliferator-activated receptor gamma (PPARG) and the adiponectin (ADIPOQ) genes. In 216 schizophrenic patients receiving antipsychotics for up to 14 weeks, we investigated single-nucleotide polymorphisms in or near PPARG (N=24) and ADIPOQ (N=18). Statistical analysis was done using ANCOVA in SPSS. Haplotype analysis was performed in UNPHASED 3.1.4 and Haploview 4.2. None of the PPARG or ADIPOQ variants showed significant association with antipsychotic-induced weight gain in our combined sample or in a refined subsample of patients of European ancestry treated with clozapine or olanzapine after correction for multiple testing. Similarly, no haplotype association could withstand multiple test correction. Although we could not find a significant influence of ADIPOQ and PPARG on antipsychotic-induced weight gain, our comprehensive examination of these two genes contributes to understanding the biology of this serious side effect. More research on glucose metabolism genes is warranted to elucidate their role in metabolic changes during antipsychotic treatment.",
keywords = "Clozapine, Glucose-related genes, Haplotypes, Olanzapine, Pharmacogenetics, Polymorphisms",
author = "Brandl, {Eva J.} and Tiwari, {Arun K.} and Zai, {Clement C.} and Chowdhury, {Nabilah I.} and Lieberman, {Jeffrey A.} and Meltzer, {Herbert Y.} and Kennedy, {James L.} and M{\"u}ller, {Daniel J.}",
note = "Funding Information: HYM has received funding grants or is or was a consultant to Abbott Labs, ACADIA, Alkemes, Bristol Myers Squibb, DaiNippon Sumitomo, Eli Lilly, EnVivo, Janssen, Otsuka, Pfizer, Roche, Sunovion, and BiolineRx. HYM is a shareholder of ACADIA and Glaxo Smith Kline. In the past three years JAL reports having received research funding or is a member of the advisory board of Allon, AlkermesBioline, GlaxoSmithKline Intracellular Therapies, Lilly, Merck, Novartis, Pfizer, Pierre Fabre, Psychogenics, F. Hoffmann-La Roche Ltd., Sepracor (Sunovion) and Targacept. JAL received no direct financial compensation or salary support for participation in these researches, consulting, or advisory board activities. JLK has been a consultant to GSK, Sanofi-Aventis, and Dainippon-Sumitomo. AKT: recipient of NARSAD 2010 young investigator award. CCZ: recipient of NARSAD Young Investigator Award; postdoctoral fellowship from the American Foundation for Suicide Prevention ( 2PDF-00065-1208-0609-1209 ), and Eli Lilly Canada . NIC: OMHF Research Studentship. DJM: CIHR Operating Grant (Genetics of antipsychotics induced metabolic syndrome, MOP 89853 ); NARSAD Independent Investigator Award, Early Researcher Award by the Ministry of Research and Innovation of Ontario, CIHR Michael Smith New Investigator Salary Prize for Research in Schizophrenia, and OMHF New Investigator Fellowship. JLK: recipient of a CIHR Operating Grant ( MOP 115097 ). ",
year = "2014",
month = oct,
day = "30",
doi = "10.1016/j.psychres.2014.05.031",
language = "English (US)",
volume = "219",
pages = "255--260",
journal = "Psychiatry Research",
issn = "0165-1781",
publisher = "Elsevier Ireland Ltd",
number = "2",
}
